ArticlePLoS neglected tropical diseases2026
Comparison of a recombinant endonuclease III protein and its synthetic peptides in ELISA for the diagnosis of tegumentary leishmaniasis using human serum and urine samples: A preliminary study.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe laboratory diagnosis of tegumentary leishmaniasis (TL) remains challenging, mainly because of the variable sensitivity and specificity of tests used. Moreover, biological samples are typically collected through invasive procedures. In this pilot study, the recombinant Leishmania endonuclease III (rENDO) protein and two specific B-cell epitopes predicted from its amino acid sequence were evaluated as diagnostic antigens for TL, by using paired serum and urine samples from patients. METHODOLOGY/PRINCIPAL
findingsrENDO protein, two synthetic peptides and a Soluble Leishmania Antigen (SLA) extract as comparator, were used to develop an ELISA that was tested with a controlled panel of paired urine and serum samples from 175 patients. Results showed that the serum-based ELISA reported sensitivity of 100% for rENDO, Peptide 1, and Peptide 2, and of 85.0% for SLA. Specificity values were of 100%, 100% and 96.6% for the protein and peptides, and 67.3% for SLA, respectively. For the urine-based ELISA, sensitivity was also of 100% for rENDO, Peptide 1, and Peptide 2, and of 90.6% for SLA. Specificity values were 100%, 100% and 96.5%, for the protein and peptides, and 91.5% for SLA, respectively. The antibody response was compared with a commercial kit, and results showed a kappa index higher than 0.90 for rENDO using both serum and urine samples, whereas the kit showed values below 0.80. Additionally, a one-point longitudinal study for antibody response monitoring in treated ML patients revealed a drop in rENDO-specific IgG levels of nearly 50% after six months.
conclusionsPreliminary data suggest that the ELISA using rENDO and its derived peptides demonstrated good sensitivity and specificity for identifying TL cases, and the rENDO-based assay could potentially have a role in monitoring the treatment of TL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.